The rule, which is part of President Donald Trump's blueprint to rein in high drug costs, sparked immediate push back from pharmaceutical companies. Beyond the industry, experts are skeptical that the regulation would do anything to bring down prices and may confuse patients because consumers often don't pay the list price for medications.

from Kaiser Health News https://ift.tt/2Ck1AHW

Related Posts:

0 comments:

Post a Comment

Popular Posts